🔎 Trials Near Me

ホーム › 頭頸部扁平上皮癌 › イリノイ州 › Chicago

Chicago、ILにおける頭頸部扁平上皮癌の臨床試験

Chicagoとその周辺地域(約30マイル以内)の拠点で、頭頸部扁平上皮癌に関する26件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。

公式研究テキスト(英語)

ここで研究参加者を募集していますか? このページの上部に表示できます — 30日間 $99 →

High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer

被験者募集中第3相
  • Advocate Illinois Masonic Medical Center, Chicago
18歳以上 · 全性別 · 2026/10/02更新 · NCT06992427

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

被験者募集中第1相
  • University of Chicago Hospital, Chicago
18歳以上 · 全性別 · 2026/10/02更新 · NCT06465069

FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

被験者募集中第2/3相
  • Captain James A Lovell Federal Health Care Center-VA North Chicago (Site # 133), Chicago
18歳以上 · 全性別 · 2026/10/02更新 · NCT06788990

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

被験者募集中第1相
  • Exelixis Clinical Site #26, Chicago
18歳以上 · 全性別 · 2026/10/01更新 · NCT05176483

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

被験者募集中第3相
  • University of Chicago Comprehensive Cancer Center, Chicago
  • Advocate Illinois Masonic Medical Center, Chicago
18歳以上 · 全性別 · 2026/10/01更新 · NCT06589804

A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

被験者募集中第3相
  • Rush University Medical Center Rush University Cancer Center Chicago, Chicago
  • The University of Chicago Medical Center (UCMC), Chicago
18歳以上 · 全性別 · 2026/09/25更新 · NCT07276399

A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer

被験者募集中第1/2相
  • The University of Chicago Medical Center (UCMC), Chicago
18歳以上 · 全性別 · 2026/09/25更新 · NCT06385080

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

被験者募集中第2相
  • Northwestern University, Chicago
  • University of Illinois, Chicago
18歳以上 · 全性別 · 2026/09/25更新 · NCT05136196

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

被験者募集中第2相
  • Northwestern University, Chicago
  • John H Stroger Jr Hospital of Cook County, Chicago
  • University of Illinois, Chicago
18歳〜79歳 · 全性別 · 2026/09/22更新 · NCT04671667

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

被験者募集中第1相
  • Northwestern University Feinberg School of Medicine, Chicago
18歳以上 · 全性別 · 2026/09/21更新 · NCT05983432

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

被験者募集中第2相
  • John H Stroger Jr Hospital of Cook County, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
  • Advocate Illinois Masonic Medical Center, Chicago
18歳以上 · 全性別 · 2026/09/14更新 · NCT02734537

A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)

被験者募集中観察研究
  • Northwestern University Feinberg School of Medicine, Chicago
18歳以上 · 全性別 · 2026/09/03更新 · NCT06163534

Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

被験者募集中第2/3相
  • Northwestern University, Chicago
  • Rush MD Anderson Cancer Center, Chicago
18歳以上 · 全性別 · 2026/08/17更新 · NCT04333537

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

被験者募集中第2相
  • Northwestern University, Chicago
18歳以上 · 全性別 · 2026/08/17更新 · NCT06532279

Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin

被験者募集中第3相
  • Northwestern University, Chicago
18歳以上 · 全性別 · 2026/08/17更新 · NCT07441681

SMP-3124LP in Adults With Advanced Solid Tumors

被験者募集中第1/2相
  • Northwestern Medicine Cancer Center, Chicago
  • The University of Chicago, Chicago
18歳以上 · 全性別 · 2026/08/12更新 · NCT06526819

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

被験者募集中第1相
  • UChicago Medicine - River East, Chicago
  • The University Of Chicago, Chicago
  • University of Chicago Medical Center, Chicago
18歳以上 · 全性別 · 2026/07/06更新 · NCT04389632

A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors

被験者募集中第1/2相
  • The University of Chicago Medical Center - Oncology, Chicago
18歳以上 · 全性別 · 2026/06/29更新 · NCT06747585

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

被験者募集中第1相
  • University of Illinois Hospital and Health Sciences System /ID# 251750, Chicago
  • University of Chicago Medical Center /ID# 276271, Chicago
18歳以上 · 全性別 · 2026/06/23更新 · NCT05005403

A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer

被験者募集中第2相
  • University of Chicago Comprehensive Cancer Center, Chicago
18歳以上 · 全性別 · 2026/05/12更新 · NCT05420948

A Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subjects With Oral and Lung Cancers

被験者募集中第2/3相
  • The University of Chicago, Chicago
18歳〜100歳 · 全性別 · 2026/04/23更新 · NCT05893888

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

被験者募集中第3相
  • University of Illinois Cancer Center, Chicago
18歳以上 · 全性別 · 2026/04/09更新 · NCT06064877

Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer

被験者募集中第1相
  • The University of Chicago, Chicago
18歳以上 · 全性別 · 2026/03/04更新 · NCT05526924

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

被験者募集中第1相
  • The University of Chicago Comprehensive Cancer Center, Chicago
18歳以上 · 全性別 · 2026/02/13更新 · NCT06778863

A Study of NX-1607 in Adults With Advanced Malignancies

被験者募集中第1相
  • University of Chicago, Chicago
18歳以上 · 全性別 · 2025/09/09更新 · NCT05107674

他の都市における頭頸部扁平上皮癌の試験

Chicagoにおける他の研究

ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。